Compare BioNano Genomics Inc (BNGO) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Kaltura Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Kaltura Inc trades at $1.64 (market cap $249.42M). The key difference: Kaltura Inc is far larger — about 18.3× BioNano Genomics Inc's market cap, and Kaltura Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | KLTR | |
|---|---|---|
Market Cap | $13.66M | $249.42M |
Sector | Health | Technology |
52-Week High | $4.92 | $1.89 |
52-Week Low | $1.06 | $1.08 |
Enterprise Value | $16.26M | $261.64M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Kaltura (KLTR) trades at $1.58, down 3.66% today, with a bullish technical outlook supported by moving averages. The company shows improving fundamentals with revenue stabilizing around $181M and net losses narrowing from -$68M in 2022 to -$12M in 2025. Recent Q2 2026 earnings beat expectations, and the company has received multiple industry recognitions for its AI and video platform leadership.
While Kaltura demonstrates operational improvement and strong analyst support (44% buy ratings), significant risks remain including persistent negative ROE (-134%), high valuation multiples (EV/EBITDA 336x), and insider selling. The stock offers speculative upside if AI initiatives drive profitability, but requires careful risk management given current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
